TABLE 1.
Descriptive characteristics of our cohort of early stage colorectal cancer patients, shown overall and by category of baseline VAT radiodensity (n = 3023)1
| Characteristic | Overall | Low density, >1 SD lower than mean, n = 404 | Within 1 SD of mean, n = 2132 | High density, >1 SD higher than mean, n = 487 |
|---|---|---|---|---|
| Age in years, mean (SD) | 62.5 (11.5) | 62.9 (10.6) | 62.5 (11.3) | 62.5 (12.9) |
| BMI, kg/m2, mean (SD) | 27.6 (5.3) | 30.5 (4.6) | 28.2 (5.0) | 22.6 (3.8) |
| VAT area, cm2, mean (SD) | 152.4 (107.4) | 269.0 (103.9) | 156.0 (91.5) | 40.0 (45.7) |
| SAT area, cm2, mean (SD) | 203.5 (106.7) | 238.6 (102.0) | 216.6 (103.6) | 116.7 (75.5) |
| Skeletal muscle tissue area, cm2, mean (SD) | 139.9 (37.6) | 154.1 (37.4) | 140.9 (37.5) | 123.4 (31.6) |
| Neutrophil/lymphocyte ratio, mean (SD) | 4.8 (5.3) | 4.8 (5.7) | 4.7 (5.2) | 5.6 (5.7) |
| Subcutaneous adipose density, HU, mean (SD) | −96.6 (9.3) | −102.6 (4.8) | −98.4 (5.9) | −83.6 (12.5) |
| Visceral adipose density, HU, mean (SD) | −87.1 (8.0) | −97.8 (2.3) | −88.2 (4.2) | −73.4 (4.8) |
| Charlson Comorbidity Index, mean (SD) | 0.8 (1.3) | 0.9 (1.4) | 0.8 (1.3) | 0.8 (1.4) |
| Race/ethnicity, n (%) | ||||
| Non-Hispanic White | 1954 (64.6%) | 275 (68.1%) | 1353 (63.5%) | 326 (66.9%) |
| Black/African American | 215 (7.1%) | 17 (4.2%) | 157 (7.4%) | 41 (8.4%) |
| Hispanic/Latino | 337 (11.1%) | 53 (13.1%) | 253 (11.9%) | 31 (6.4%) |
| Asian/Pacific Islander | 500 (16.5%) | 55 (13.6%) | 357 (16.7%) | 88 (18.1%) |
| Other | 17 (0.6%) | 4 (1.0%) | 12 (0.6%) | 1 (0.2%) |
| Sex, n (%) | ||||
| Male | 1515 (50.1%) | 262 (64.9%) | 1069 (50.1%) | 184 (37.8%) |
| Female | 1508 (49.9%) | 142 (35.1%) | 1063 (49.9%) | 303 (62.2%) |
| Smoking history, n (%) | ||||
| Never | 1418 (46.9%) | 187 (46.3%) | 998 (46.8%) | 233 (47.8%) |
| Former | 1241 (41.1%) | 186 (46.0%) | 876 (41.1%) | 179 (36.8%) |
| Current | 364 (12.0%) | 31 (7.7%) | 258 (12.1%) | 75 (15.4%) |
| Stage, n (%) | ||||
| I | 917 (30.3%) | 159 (39.4%) | 626 (29.4%) | 132 (27.1%) |
| II | 945 (31.3%) | 119 (29.5%) | 666 (31.2%) | 160 (32.9%) |
| III | 1161 (38.4%) | 126 (31.2%) | 840 (39.4%) | 195 (40.0%) |
| Cancer site, n (%) | ||||
| Rectum | 885 (29.3%) | 136 (33.7%) | 615 (28.8%) | 134 (27.5%) |
| Colon | 2138 (70.7%) | 268 (66.3%) | 1517 (71.2%) | 353 (72.5%) |
| Receipt of radiation therapy, n (%) | ||||
| No | 2552 (84.4%) | 344 (85.1%) | 1793 (84.1%) | 415 (85.2%) |
| Yes | 471 (15.6%) | 60 (14.9%) | 339 (15.9%) | 72 (14.8%) |
| Receipt of chemotherapy, n (%) | ||||
| No | 1440 (47.6%) | 216 (53.5%) | 985 (46.2%) | 239 (49.1%) |
| Yes, adjuvant | 1206 (39.9%) | 140 (34.7%) | 868 (40.7%) | 198 (40.7%) |
| Yes, neoadjuvant | 377 (12.5%) | 48 (11.9%) | 279 (13.1%) | 50 (10.3%) |
1
HU, Hounsfield Unit; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.